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A B S T R A C T
Introduction: Intramuscular injection of botulinum toxin (BoNTA) is one of the primary treatments for
focal spasticity. This treatment is considered costly and the level of reimbursement by health insurance
has been decreasing in many countries for several years. The aim of this study was to determine the real
cost of treating spasticity with BoNTA and to compare this with the level of reimbursement by the
national health insurance in France in 2008 and with a new fee, speciﬁc to the injection of BoNTA in
ambulatory services.
Method: A single-center, retrospective study using the 2008 database from a French secondary-care day-
hospital unit (treating spasticity in adults with sequelae of stroke, multiple sclerosis or traumatic brain
injuries). The level of reimbursement by the French ministry of health for BoNTA treatment for adults
with spasticity constituted the ‘‘calculated cost’’ and corresponded to the hospital’s ‘‘budget’’. The ‘‘real
cost’’ (incurred by the hospital) included the sum of stafﬁng and material costs as well as the number of
toxin vials used. The calculated costs for 2009 and 2013 were based on the levels of reimbursement
during those years. The difference between real and calculated cost for 2009 and 2013 was estimated
considering that the real cost of 2008 was stable.
Results: In 2008, 364 patients received BoNTA, resulting in 870 day-hospital admissions. The calculated
cost was 459,056 s/year and the real cost was 567,438 s/year (equivalent to 4.27 s/day/patient). The
total budget deﬁcit (hospital income minus hospital costs) was 108,383 s. The deﬁcit was estimated at
222,892 s in 2009 and 241,188 s in 2013.
Conclusion: The daily cost of BoNTA treatment for spasticity is reasonable; however, because of the level
of reimbursement by the national health insurance in France, the treatment is costly for French hospitals.




The main treatment for focal spasticity is intramuscular
injection of type A botulinum toxin (BoNTA) [1]. Many studies
have demonstrated patient satisfaction and functional improve-
ment with this treatment [2–5].
Medico-economic studies of the ﬁnancial impact of BoNTA
treatment are generally based on the Delphi method. The results
have generally shown that BoNTA treatment is cost-effective [6–12],
mainly because of reduced indirect costs such as those related to
fractures and hospital admissions after spasticity-related falls.
However, more detailed analyses of the initial cost of the treatment
are lacking. A recent prospective study in England compared the cost* Corresponding author. Tel.: +33 1 47 10 70 68; fax: +33 1 47 10 70 73.
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.of BoNTA treatment for the upper limb with that of classical
rehabilitation in 150 adult patients [10] and found no difference in
cost-effectiveness at 3 months. The methods used to evaluate costs
were not clearly described but appeared to be global. Most studies
have focused on the difference in cost and effectiveness between
rehabilitation alone and rehabilitation with BoNTA injections [6–
13]. One study analysed the speciﬁc costs of BoNTA treatment for
spasticity, taking into account all elements related to the treatment
(toxin, stafﬁng, equipment, etc.): the cost (about 1300 s/year) was
high and was greater than the cost with its use for other symptoms
such as spasmodic torticollis and blepharospasm [14].
The incidence of nervous system disorders causing spasticity is
relatively high. For example, in France, stroke causes 100,000
hospital admissions per year [15]. Spasticity will develop in an
estimated one third of these patients [16]. Therefore, the
evaluation of costs relating to the treatment of spasticity is a
public health issue, and improved knowledge of the average cost of
Fig. 1. Distribution of spending for treating spasticity per treatment session in the
day-hospital in 2008. BoNTA: botulinum toxin type A; other costs: costs relating to
functioning not including housing costs.
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treatment not sufﬁciently covered by government health insur-
ance could inhibit the development of its use in physical medicine
and rehabilitation (PMR) departments and reduce its availability to
patients.
The aim of this study was to determine the average cost of
BoNTA treatment for spasticity in an adult day-hospital setting and
compare the cost to the level of reimbursement by the national
health insurance in France in 2008, 2009 and 2013.
2. Methods
The study was designed as a single-centre retrospective study in a
secondary-care day-hospital unit specialised in treating spasticity in
adults. Data for BoNTA treatment in 2008 were extracted from day-
hospital reports, le programme de me´dicalisation des syste`mes
d’information (PMSI; a computerized classiﬁcation system that
classiﬁes hospital admissions as a function of both disease and the
nature and degree of the related costs) and the pharmacy register.
These data were crossed and used to calculate the ‘‘calculated cost’’,
which was then compared with the ‘‘real cost’’ of treatment.
2.1. Calculation of the ‘‘calculated cost’’ of treatment with BoNTA
In France, BoNTA can only be administered to patients who are
admitted to a hospital, health-care centre or day-hospital (hospital
use only; Article R. 5121-83 of the French Public Health Code). It
can be administered within a secondary- or tertiary-care setting
(in France, secondary-care includes medicine, surgery and obstet-
rics, and tertiary-care includes long-term care and rehabilitation).
In tertiary-care, the toxin is funded from the hospital’s annual
budget or by the daily rate in private centres, which is submitted to
the Quantiﬁed National Target on expenditures. This type of
funding takes no account of the number of treatments and doses
administered.
In secondary-care, the treatment is funded only by the case-
mix–based hospital prospective payment system (T2A). In this
system, resources are allocated after assessment of the level of
activity produced. The value of each activity is ﬁxed annually by
the health minister via the homogeneous hospital-stay group/
homogeneous patient group (GHS/GHM) mechanism (adapted
from the US ‘‘diagnostic related groups’’). The patient classiﬁcation
system (PMSI) is used to assign each patient’s stay in a GHM to
which one (or sometimes several) GHSs are associated. The group
determines the level of reimbursement by the national health
insurance. In acute secondary-care departments (such as that in
which the present study was carried out), the patient must be
admitted in order to receive BoNTA. Thus, the level of reimburse-
ment is determined by the GHM assigned to the patient. In 2008,
GHMs differed depending on the pathology (stroke, cerebral palsy,
traumatic brain injury, etc.) and type of symptoms (claw hand,
equinus, varus foot, etc.). We used the PMSI code for BoNTA
injection (acte CCAM PCLB003) to search the database for all
BoNTA injections that had been performed in specialised day-
hospitals in 2008. The values for each patient’s GHM were then
summed. This sum constituted the ‘‘calculated cost’’ and corre-
sponded to the hospital’s ‘‘income’’ for 2008.
In 2009, a speciﬁc GHM (GHM 01K04J) was created to ensure
funding for botulinum toxin in ambulatory care. This GHM was
homogenous for all patients treated with botulinum toxin and was
attributed a fee of 396.03 s in 2009 (version 10 of the GHM). The
fee has been lowered each year since then, decreasing to 375 s in
2013 (version 11 of the GHM). The calculated cost was estimated
for 2009 and 2013 by using the GHM fees for those years, based on
the number of patients treated in 2008.2.2. Calculation of the ‘‘real costs’’ of treatment with BoNTA
Patients were recalled every 3 months for repeat injections. The
PMR physicians (all part-time) performed the evaluations and
follow-up as well as the injections. They were assisted by one nurse
(full-time) and one nursing assistant. The nurse and assistant
managed the appointments and all the administration.
All patients had central nervous system lesions with spasticity.
The injections were often multi-site, with 3 to 10 muscle groups
injected. Muscles were located by using electromyographic
stimulation and patients were given inhaled nitrous oxide to aid
relaxation. Each session lasted from 30 to 45 min depending on the
number of muscles treated and any technical difﬁculties.
In 2008, 2 drugs were available: Botox1 (100 UI/vial) and
Dysport1 (500 UI/vial).
The real cost of the BoNTA injections in the day-hospital was
determined by summing the cost of staff, treatment, small
equipment used, and consumables for 2008. This information was
obtained from the ﬁnance department and the manager in charge of
the unit. The cost was considered stable for 2009 and 2013 because
of only minor changes in the costs incurred by our hospital between
2008 and 2013 (vials, medical material and salaries, etc.).
3. Results
In 2008, there were 870 day-hospital admissions involving
364 patients. The mean number of treatment sessions per patient
was 2.39 (range 1–4). Botox1 was used in 809 treatment sessions
(2474 vials, mean dose 291  140 units/session) and Dysport1 in
61 sessions (97 vials, mean dose 757  325 units/session).
3.1. Real cost
To calculate the real cost of treatment, the costs incurred in
2008 were summed from the following: one part-time PMR
doctor = 57,046 s/year; one full-time nurse + 1 part-time assis-
tant = 81,524 s/year; medical material (needles, sterile gloves,
swabs, nitrous oxide, etc.) and administrative material (consum-
ables, computers, printers, etc.) = 44,455 s/year; type A botulinum
toxin (Botox1 and Dysport1) = 384,413 s. The total real cost in
2008 was 567,438 s. The mean real cost per patient treated was
1559 s/year (4.27 s/day) and the mean cost per treatment session
was 652.23 s.
3.2. Calculated cost
In 2008, the hospital received 459,056 s for the treatment of
spasticity by BoNTA, based on the cost calculated by multiplying
Table 1
Studies of mean cost of intramuscular injection of botulinum toxin A for treating spasticity in adults.
Authors Number of patients included Symptoms Mean cost (s) Variables studied
Burbaud et al. [14] 122 UL spasticity 1233/year Cost of the toxin, equipment and staff
Burbaud et al. [14] 143 LL spasticity 1321/year Cost of the toxin, equipment and staff
de Andre´s-Nogales et al. [11] NA, evaluation Adults with spasticity 794/year Cost of the toxin
Svensson et al. [12] 16 MS-related spasticity 223/year Cost of the toxin
Ward et al. [9] NA evaluation Stroke-related wrist spasticity 943/year Cost of the toxin
Shaw et al. [10] 333 Stroke-related UL spasticity 222/session Cost of the toxin and consultation
NA: non-attributed; UL: upper limb; LL: lower limb; MS: multiple sclerosis.
Fig. 2. Distribution of spending for treating spasticity per treatment session
according to the national scale of costs. BoNTA: botulinum toxin type A; other costs:
costs relating to functioning including housing costs.
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fee for the speciﬁc GHM for spasticity in the day-hospital
(527.65 s) (Fig. 1). The mean calculated cost per patient treated
was 1261 s/year (3.45 s/day) and the mean cost per treatment
session was 527.65 s.
In 2008, the total funding deﬁcit (hospital revenue minus
hospital costs) was 108,382 s, equivalent to 125 s per treatment
session. Considering the real cost to be stable, the deﬁcit was
estimated at 222,892 s in 2009 (567,438  870  396.03 s) and
241,188 s in 2013 (567,438  870  375 s) because of the new
fees in those years (396.03 s in 2009 and 375 s in 2013).
4. Discussion
This retrospective study including a large sample of patients
who had received BoNTA for focal spasticity in France showed a
ﬁnancial deﬁcit related to spending/valuation. However, the real
cost of treatment per day (4.27 s) appeared to be reasonable,
especially as compared with that for oral baclofen (up to 1.80 s/
day) or intermittent self-catheterisation (20 s/day).
The cost of BoNTA treatment has been evaluated in previous
studies, but most considered only the cost of the toxin itself
(Table 1). Burbaud et al. performed a large study of the real cost of
treatment for different conditions in a French health centre [13]
and found that the cost of multi-site treatment for spasticity was
6.58  1.38 s/day, which is similar to the present ﬁndings. Moreover,
the authors showed that spasticity was 9 times more expensive to
treat than hemifacial spasm and twice as expensive to treat as
spasmodic torticollis. The authors suggested that this cost was mostly
due to the large doses of botulinum toxin required for treating
spasticity. Comparing the results of the present study with those of
other studies is difﬁcult because the aims slightly differed; other
studies mostly focused on the cost-effectiveness ratio and not the real
cost of BoNTA injections.
With regard to problems relating to the funding of BoNTA
treatment, the real cost relative to the valuation of BoNTA
treatment for patients with spasticity needed to be clearly deﬁned,
particularly because a large number of patients receive this
treatment in our hospital. The ‘‘real cost’’ per treatment session per
year was 652.23 s and the reimbursement per treatment session
was 527.65 s, for a deﬁcit of 108,383 s/year for the hospital. This
is a large deﬁcit, but considering the potential costs of complica-
tions avoided (fractures, bedsores, etc.), it seems acceptable. This
observation is similar to that made by Zoons et al. in a recent
medico-economical study of the impact of botulinum toxin
treatment for focal dystonia [17].
In France, health-care related expenses for chronic diseases
such as stroke, paraplegia, and multiple sclerosis, including all
patients with spasticity, are fully reimbursed by the national
health insurance. In addition, BoNTA is reserved for hospital use. In
France, patients who are hospitalized cannot be charged for this
category of drug. The cost is funded by hospitals and included in
the GHS for secondary-care and in the hospital’s annual budget for
tertiary-care. There are no extra charges for patients according tothe French Public Health Code. Therefore, patients incur no charges
for this spasticity treatment. However, the method of funding in
tertiary-care departments (with no funding other than the annual
budget) greatly limits its use for spasticity in these centres. As well,
in secondary-care, the low GHM valuation demonstrated in this
study limits its use.
Such ﬁnancial constraints have affected treatment. For exam-
ple, there are regional inequalities, patients may have to attend
centres far from their homes, and clinicians cannot always follow
the recommendations regarding doses or timing of repeat
injections, for example. Therefore, the valuation of this treatment
must be improved.
The GHM rate covers costs as long as the treatment is limited to
weak doses of BoNTA per patient. According to data from ENC 2011
(ATIH – 2011 DGF Re´fe´rentiel v11e), the decomposition of GHM
01K04J (for all conditions) (Figs. 1 and 2) indicates that the drug
itself (mean cost = 105 s) represents 22% of the mean cost to the
GHM (estimated at 481 s). However, from our study, with BoNTA
used speciﬁcally for treating spasticity, the drug itself constitutes
almost 68% of the calculated cost of a day-hospital treatment
session (652.23 s) (Fig. 1) (equal to 441.90 s), mainly because the
doses of BoNTA necessary for treating spasticity are much greater
than previously estimated.
In Spain and Italy, funding botulinum toxin for spasticity is not
an issue because botulinum toxin is a hospital drug that is
separately reimbursed by the national health insurance in those
countries, with no charge to the patient. The situation is similar in
the United Kingdom, where botulinum toxin is mainly used in the
hospital setting (secondary-care) and is reimbursed separately as a
high-cost drug with no patient charges.
The determination of a new GHS fee for secondary-care speciﬁc
for treating spasticity and taking into account the real doses of
BoNTA dispensed is essential to ensure complete funding for this
treatment, including all resources involved. Another option would
be to consider separate funding by the national health insurance
for BoNTA as a high-cost drug, as in other European countries.
The study has some limitations. It was a retrospective study,
which may not have been exhaustive. However, all attempts were
made to be as exhaustive as possible by comparing 3 formal
A. Schnitzler et al. / Annals of Physical and Rehabilitation Medicine 58 (2015) 265–268268registers (medical, medical-administrative and pharmacy) that are
managed by the hospital’s department of medical information. The
study was facilitated by the speciﬁcity of the unit in which it was
carried out because the sole activity of this unit is treating spasticity
with BoNTA. Housing costs were not taken into consideration
(use of facilities, water and electricity, etc.) or patient transport;
however, these costs are difﬁcult to calculate and because they
vary among centres, difﬁcult to interpret. The recent commercia-
lisation of Botox1 50 and 200 U and Dysport1 300 U has facilitated
the adjustment of doses, and costs are decreasing, probably in part
because of the estimations carried out in 2009 and 2013. Finally, we
could not clearly identify the different aetiologies of spasticity.
The patients receiving care in this unit were often severely disabled
and required large doses of BoNTA.
5. Conclusion
BoNTA injections are currently the primary treatment for focal
spasticity. Because of the high incidence of central nervous system
disorders (such as stroke), precisely establishing the costs and
spending related to this treatment as well as its valuation is
essential. The results of this retrospective study of a large sample of
patients receiving treatment for focal spasticity showed a deﬁcit
related to spending/valuation, but the mean daily cost (4.27 s)
was reasonable. Because of the annual reduction in reimbursement
for the treatment, the total hospital budget deﬁcit was 222,892 s
in 2009 and 241,188 s in 2013. This treatment should be re-
valuated to avoid suboptimal clinical practices.
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